Skip to main
ABVX
ABVX logo

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Abivax SA has reported promising findings from its Phase 2 trials for the drug candidate obefazimod, indicating significant improvements in average change from baseline in key metrics, which supports a strong foundation for its ongoing Phase 3 clinical trials for ulcerative colitis. The drug demonstrates compelling efficacy and a favorable safety profile, positioning it as a potential early treatment option prioritized over current advanced therapies for inflammatory bowel diseases. Confidence in the success of the upcoming ABTECT Phase 3 trial stems from its strong Phase 2 results, indicating a robust potential for clinical adoption and market acceptance in the treatment of chronic inflammatory diseases.

Bears say

Abivax SA has a history of sustained financial losses and has yet to achieve profitability, which presents significant concerns regarding its long-term viability. The company faces several risks, including potential failure in meeting crucial efficacy endpoints in clinical trials, regulatory challenges, and complications in securing acceptable partnerships that could jeopardize future commercial launches. Additionally, litigation risks and potential market conditions may hinder the successful commercialization of its candidates, further exacerbating the risks to its financial outlook.

Abivax SA (ABVX) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 9 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.